title: Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice.
abstract: The potency test for the anthrax vaccine currently licensed for human use in the United States (Anthrax Vaccine Adsorbed) involves the protection of actively immunized guinea pigs from a lethal challenge with a virulent strain of Bacillus anthracis. Lethal challenge tests entail the use of specialized containment facilities for the safe and secure handling of the challenge strain. This potential difficulty, plus humane considerations, have prompted us to investigate non-lethal, alternative immunogenicity assays that could be considered as potency tests not only for the current vaccine, but also for vaccines under development. Immunogenicity tests will require suitable measurement of an antibody response to relevant antigens, by methods such as enzyme linked immunosorbent assay (ELISA) or a toxin neutralization assay. Any assay chosen for this purpose should be adequately validated and reproducible by other laboratories. Validation of an analytical procedure requires the demonstration that the assay is suitable for its intended purpose. The objective of this work was to study the performance of an anti-PA-ELISA designed to assess the antibody response to anthrax vaccines in mice. Validation studies were performed according to the guidelines of the International Conference of Harmonization (ICH), and we have established the working range of the assay (37-1159 EU/mL) on the bases of the following parameters: linearity (20-1159 EU/mL; r2=0.99; p-value=0.21), accuracy (91-118% recovery), precision (< or =20%CV, repeatability; < or =9 and < or =21%CV, intermediate precision per day and per analyst, respectively), detection limit (5 EU/mL), and quantification limit (37 EU/mL). We believe that assay specificity and the above characteristics are adequate to allow this ELISA to be considered for use in a mouse immunogenicity (potency) test of anthrax vaccines, and for the standardization of reagents.
authors.affiliation: Center for Biologics Evaluation & Research, US FDA, USA.
authors.forename: María
authors.initials: M
authors.lastname: Pombo
authors.forename: Inge
authors.initials: I
authors.lastname: Berthold
authors.forename: Elise
authors.initials: E
authors.lastname: Gingrich
authors.forename: María
authors.initials: M
authors.lastname: Jaramillo
authors.forename: Mary
authors.initials: M
authors.lastname: Leef
authors.forename: Lev
authors.initials: L
authors.lastname: Sirota
authors.forename: Henry
authors.initials: H
authors.lastname: Hsu
authors.forename: Juan
authors.initials: J
authors.lastname: Arciniega
mesh_terms: D000818:Animals; D022122:Anthrax Vaccines / Q000008:administration & dosage; D000907:Antibodies, Bacterial / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D051379:Mice; D008807:Mice, Inbred BALB C; D012680:Sensitivity and Specificity
chemical_list: D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial